These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38744100)

  • 1. Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110).
    Boukovala M; Modest DP; Ricard I; Fischer von Weikersthal L; Decker T; Vehling-Kaiser U; Uhlig J; Schenk M; Freiberg-Richter J; Peuser B; Denzlinger C; Peveling Genannt Reddemann C; Graeven U; Schuch G; Schwaner I; Heinrich K; Neumann J; Jung A; Held S; Stintzing S; Heinemann V; Michl M
    ESMO Open; 2024 May; 9(5):103374. PubMed ID: 38744100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110).
    Heinrich K; Modest DP; Ricard I; Fischer von Weikersthal L; Decker T; Kaiser F; Graeven U; Uhlig J; Schenk M; Freiberg-Richter J; Peuser B; Denzlinger C; Giessen-Jung C; Stahler A; Michl M; Held S; Jung A; Kirchner T; Stintzing S; Heinemann V
    Eur J Cancer; 2021 Apr; 147():128-139. PubMed ID: 33647548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer.
    Tsuchihashi K; Ito M; Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama A; Denda T; Satake H; Suto T; Sugimoto N; Katsumata K; Ishikawa T; Kashiwada T; Oki E; Komatsu Y; Okuyama H; Sakai D; Ueno H; Tamura T; Yamashita K; Kishimoto J; Shimada Y; Baba E
    Clin Colorectal Cancer; 2018 Dec; 17(4):e687-e697. PubMed ID: 30149986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI trial (AIO KRK 0110).
    Stahler A; Modest DP; Fischer von Weikersthal L; Kaiser F; Decker T; Held S; Graeven U; Schwaner I; Denzlinger C; Schenk M; Kurreck A; Heinrich K; Gießen-Jung C; Neumann J; Kirchner T; Jung A; Stintzing S; Heinemann V
    Eur J Cancer; 2022 Sep; 173():194-203. PubMed ID: 35940054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer.
    Fujita Y; Taguri M; Yamazaki K; Tsurutani J; Sakai K; Tsushima T; Nagase M; Tamagawa H; Ueda S; Tamura T; Tsuji Y; Murata K; Taira K; Denda T; Moriwaki T; Funai S; Nakajima TE; Muro K; Tsuji A; Yoshida M; Suyama K; Kurimoto T; Sugimoto N; Baba E; Seki N; Sato M; Shimura T; Boku N; Hyodo I; Yamanaka T; Nishio K
    Oncologist; 2019 Mar; 24(3):327-337. PubMed ID: 30425180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study).
    Nakayama G; Mitsuma A; Sunagawa Y; Ishigure K; Yokoyama H; Matsui T; Nakayama H; Nakata K; Ishiyama A; Asada T; Umeda S; Ezaka K; Hattori N; Takami H; Kobayashi D; Tanaka C; Kanda M; Yamada S; Koike M; Fujiwara M; Fujii T; Murotani K; Ando Y; Kodera Y
    Oncologist; 2018 Aug; 23(8):919-927. PubMed ID: 30049885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination chemotherapy with TAS-102 plus bevacizumab in salvage-line treatment of metastatic colorectal cancer: A single-center, retrospective study examining the prognostic value of the modified Glasgow Prognostic Score in salvage-line therapy of metastatic colorectal cancer.
    Matsuhashi N; Takahashi T; Fujii H; Suetsugu T; Fukada M; Iwata Y; Tokumaru Y; Imai T; Mori R; Tanahashi T; Matsui S; Imai H; Tanaka Y; Yamaguchi K; Futamura M; Yoshida K
    Mol Clin Oncol; 2019 Oct; 11(4):390-396. PubMed ID: 31475067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial).
    Stahler A; Heinemann V; Schuster V; Heinrich K; Kurreck A; Gießen-Jung C; Fischer von Weikersthal L; Kaiser F; Decker T; Held S; Graeven U; Schwaner I; Denzlinger C; Schenk M; Neumann J; Kirchner T; Jung A; Kumbrink J; Stintzing S; Modest DP
    Eur J Cancer; 2021 Nov; 157():71-80. PubMed ID: 34507244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110).
    Modest DP; Fischer von Weikersthal L; Decker T; Vehling-Kaiser U; Uhlig J; Schenk M; Freiberg-Richter J; Peuser B; Denzlinger C; Peveling Genannt Reddemann C; Graeven U; Schuch G; Schwaner I; Stahler A; Jung A; Kirchner T; Held S; Stintzing S; Giessen-Jung C; Heinemann V;
    J Clin Oncol; 2019 Jan; 37(1):22-32. PubMed ID: 30388045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer.
    Bazarbashi S; Aljubran A; Alzahrani A; Mohieldin A; Soudy H; Shoukri M
    Cancer Med; 2015 Oct; 4(10):1505-13. PubMed ID: 26207614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial.
    Giessen C; von Weikersthal LF; Hinke A; Stintzing S; Kullmann F; Vehling-Kaiser U; Mayerle J; Bangerter M; Denzlinger C; Sieber M; Teschendorf C; Freiberg-Richter J; Schulz C; Modest DP; Moosmann N; Aubele P; Heinemann V
    BMC Cancer; 2011 Aug; 11():367. PubMed ID: 21861888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of age on efficacy and early mortality of initial sequential treatment versus upfront combination chemotherapy in patients with metastatic colorectal cancer: a subgroup analysis of a phase III trial (AIO KRK0110, XELAVIRI study).
    Kurreck A; Heinemann V; Fischer von Weikersthal L; Decker T; Kaiser F; Uhlig J; Schenk M; Freiberg-Richter J; Peuser B; Denzlinger C; Graeven U; Schwaner I; Stahler A; Heinrich K; Jung A; Held S; von Einem JC; Stintzing S; Giessen-Jung C; Modest DP
    Eur J Cancer; 2020 Sep; 137():81-92. PubMed ID: 32750502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT].
    Clarke SJ; Burge M; Feeney K; Gibbs P; Jones K; Marx G; Molloy MP; Price T; Reece WHH; Segelov E; Tebbutt NC
    PLoS One; 2020; 15(3):e0229900. PubMed ID: 32142532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
    Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C
    JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
    Song A; Eo W; Lee S
    World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Australian translational study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT].
    Clarke S; Burge M; Cordwell C; Gibbs P; Reece W; Tebbutt N
    BMC Cancer; 2013 Mar; 13():120. PubMed ID: 23497305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab.
    Kotaka M; Xu R; Muro K; Park YS; Morita S; Iwasa S; Uetake H; Nishina T; Nozawa H; Matsumoto H; Yamazaki K; Han SW; Wang W; Ahn JB; Deng Y; Cho SH; Ba Y; Lee KW; Zhang T; Satoh T; Buyse ME; Ryoo BY; Shen L; Sakamoto J; Kim TW
    Chin J Cancer; 2016 Dec; 35(1):102. PubMed ID: 28007025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAF
    Tabernero J; Grothey A; Arnold D; de Gramont A; Ducreux M; O'Dwyer P; Tahiri A; Gilberg F; Irahara N; Schmoll HJ; Van Cutsem E
    ESMO Open; 2022 Oct; 7(5):100559. PubMed ID: 36029653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of inflammation-based prognostic score on mortality of patients undergoing chemotherapy for far advanced or recurrent unresectable colorectal cancer.
    Ishizuka M; Nagata H; Takagi K; Kubota K
    Ann Surg; 2009 Aug; 250(2):268-72. PubMed ID: 19638907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial.
    Denda T; Takashima A; Gamoh M; Iwanaga I; Komatsu Y; Takahashi M; Nakamura M; Ohori H; Sakashita A; Tsuda M; Kobayashi Y; Baba H; Kotake M; Ishioka C; Yamada Y; Sato A; Yuki S; Morita S; Takahashi S; Yamaguchi T; Shimada K
    Eur J Cancer; 2021 Sep; 154():296-306. PubMed ID: 34304054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.